Japanese fund moves quickly to invest in promising technology against malaria, tuberculosis and chagas disease

The Global Health Innovation and Technology Fund (GHIT Fund) announced that it will invest US$720,000 for early work on a novel vaccine candidate against TB being co-developed by Japan’s Create Vaccine Co., Ltd. and Aeras. The announcement is part of the first round of grants by GHIT Fund, a public-private partnership launched earlier this year that brings together the Japanese Government, the Bill & Melinda Gates Foundation and pharmaceutical companies.